Dr. Dipti Patel-Donnelly, MD

Dr. Patel-Donnelly practices at Virginia Cancer Specialists in Fairfax, Virginia.

Dr. Patel-Donnelly's NPI, 1427026020, was assigned on March 9, 2006. Dr. Patel-Donnelly graduated from Icahn School of Medicine at Mount Sinai in 2006. Dr. Patel-Donnelly holds Virginia license 0101234634.

Dr. Patel-Donnelly's primary practice is Virginia Cancer Specialists, at 8613 Lee Hwy # 200n #200n, Fairfax, VA 22031. The practice phone is (703) 208-3155.

Dr. Patel-Donnelly's primary practice is Virginia Cancer Specialists in Fairfax, Virginia. Dr. Patel-Donnelly is also affiliated with Inova Fair Oaks Hospital. The medical group on file is Virginia Cancer Specialists. Dmand AI also links Dr. Patel-Donnelly to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Patel-Donnelly practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Patel-Donnelly's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Patel-Donnelly is licensed in Virginia.

CMS data shows 36,278 Medicare services from Dr. Patel-Donnelly across 45 procedure codes in 2024, for 842 Medicare patients. Medicare paid $730,105 for them. Every service was in an office.

CMS counts 842 Medicare patients who saw Dr. Patel-Donnelly in 2024. The largest group is 75 to 84, with 373 patients. 74% of them have high cholesterol, and 68% have high blood pressure. 4% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Patel-Donnelly's median patient age at 66, with 65% women.

In 2024, Dr. Patel-Donnelly wrote 963 Medicare Part D claims for 127 patients. 67% of them were for generic drugs. CMS names the drug for 797 of them, across 27 drugs with 11 or more claims each, at $3,660,400 in total drug cost. In 2023, CMS named 520 claims across 22 drugs.

Dr. Patel-Donnelly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Patel-Donnelly as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Patel-Donnelly in 2018. 2018 was the busiest year, with 2. The most frequent topics are Indazoles, Pyrazines and Syk Kinase. Dr. Patel-Donnelly's most frequent co-authors are Christopher Andrew Yasenchak, MD, Wei X. Ye, MD and Wei Ye, DO.

Dmand AI links Dr. Patel-Donnelly to 5 clinical trials, 3 of them phase 2 studies. Conditions studied include Lymphoma, T-Cell, Peripheral, Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Large B-Cell, Diffuse. Seagen Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Patel-Donnelly that name 1 trial.

CMS Open Payments shows 48 general payments to Dr. Patel-Donnelly from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Amgen Inc. paid the most, $137. It also lists 3 research payments totaling $46,184 from 2018 to 2020, naming 1 clinical trial.

Dr. Patel-Donnelly graduated from Icahn School of Medicine at Mount Sinai in 2006.